CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
11 juin 2024 08h00 HE
|
CervoMed Inc.
- Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value indication expected with positive result - BOSTON, June 11, 2024 (GLOBE...
CervoMed to Appoint William Elder as Chief Financial Officer
20 mai 2024 08h00 HE
|
CervoMed Inc.
BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment...
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
15 mai 2024 08h00 HE
|
CervoMed Inc.
- CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q...
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
01 avr. 2024 08h00 HE
|
CervoMed Inc.
- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash...
CervoMed to Participate in Upcoming Investor Conferences
28 mars 2024 16h05 HE
|
CervoMed Inc.
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that...
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
28 mars 2024 08h30 HE
|
CervoMed Inc.
Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital $50 million financing upfront with up to an additional $99.4 million tied...
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
05 mars 2024 08h00 HE
|
CervoMed Inc.
- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP) - Neflamapimod effects on GFAP correlated to clinical outcomes assessed by...
CervoMed to Participate in the BIO CEO and Investor Conference
21 févr. 2024 08h00 HE
|
CervoMed Inc.
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that...
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
12 févr. 2024 08h00 HE
|
CervoMed Inc.
-Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of EEG and MRI results, substantially derisk the ongoing RewinD-LB Phase 2b...
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
07 févr. 2024 08h30 HE
|
CervoMed Inc.
Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating...